---
title: "Gilead Sciences Reports Positive Results From Phase 3 Study Of Livdelzi For Biliary Cholangitis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288430891.md"
description: "Gilead Sciences announced positive Phase 3 results for Livdelzi (seladelpar) in treating primary biliary cholangitis. The study showed significantly more patients achieved normalization of alkaline phosphatase (ALP), a key liver marker, compared to placebo after 52 weeks. The safety profile remained consistent with previous studies, with no new concerns identified."
datetime: "2026-06-02T13:08:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288430891.md)
  - [en](https://longbridge.com/en/news/288430891.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288430891.md)
---

# Gilead Sciences Reports Positive Results From Phase 3 Study Of Livdelzi For Biliary Cholangitis

Add  as your preferred news source on Google

 Add Now

Gilead Sciences, Inc. (GILD) announced Tuesday positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP).

ALP is a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP = 1.0× upper limit of normal (ULN) and a = 15% decrease from baseline.

These findings were observed in people with inadequately controlled disease, defined as having ALP levels above the ULN and below 1.67×ULN, with an incomplete response or intolerance to ursodeoxycholic acid (UDCA).

The safety profile of seladelpar observed in IDEAL was consistent with previously reported Livdelzi studies, with no new safety concerns identified.

In PBC, ALP is a key disease marker associated with disease activity and long-term outcomes. ALP levels above normal, including in the 1.0 to 1.67×ULN range, are associated with increased risk of progression to liver transplant or death compared with normalized ALP levels.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome](https://longbridge.com/en/news/288463750.md)
- [Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands](https://longbridge.com/en/news/288897369.md)
- [How Investors Are Reacting To Ipsen (ENXTPA:IPN) Expanding IQIRVO Evidence In Primary Biliary Cholangitis](https://longbridge.com/en/news/288921766.md)
- [Gilead And Lakefront Acquire Ouro Medicines In $1.67 Bln Agreement; To Co-Develop Gamgertamig](https://longbridge.com/en/news/288851463.md)
- [Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa | GILD Stock News](https://longbridge.com/en/news/288820076.md)